Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Relating to NTx(R)-265

   Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the "Company") is pleased to announce today that it has been granted a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,846,898- entitled, "Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis." The claims cover the use of luteinizing hormone (LH) or human chorionic gonadotrophin (hCG) and erythropotein (EPO) for producing neural stem cells (in vitro & in vivo), which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The covered in vivo uses include administration of these compounds to subjects having neurodegenerative conditions, diseases and CNS injuries. This is the first U.S. patent to issue in this patent family and it protects the use of the NTx®-265 regimen in the acute neurologic injury indications of Stroke, and Traumatic Brain Injury, amongst other indications.

Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows:

"We at SCT are very excited to see this patent issue as it represents an important intellectual property milestone for the NTx®-265 program. This patent offers protection and support for our NTx®-265 technology, a keystone patent, while expanding and increasing value to SCT's overall intellectual property portfolio."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX-V: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Stem Cell Therapeutics Corp. Allen Davidoff, PhD CSO 403-245-5495 ext.226 [e-mail] Stem Cell Therapeutics Corp. Angelika Goncalves DaSilva Operations Manager 403-245-5495 ext. 230 [e-mail] Stem Cell Therapeutics Corp. Michael Cook CFO 403-245-5495 ext.229 [e-mail] www.stemcellthera.com